| [1] |
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
|
| [2] |
van der Meer R, Bakkers C, Rostamkhan E, et al. Ovarian metastases from colorectal cancer in young women: a systematic review of the literature[J]. Int J Colorectal Dis, 2021, 36(12): 2567-2575.
|
| [3] |
Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence[J]. J Clin Epidemiol, 2011, 64(4): 401-406.
|
| [4] |
陈怡，张颖，王颖. 结直肠癌卵巢转移的研究现状及进展[J/CD]. 中华结直肠疾病电子杂志, 2020, 9(5): 498-501.
|
| [5] |
Kagawa H, Kinugasa Y, Yamaguchi T, et al. Impact of resection for ovarian metastases from colorectal cancer and clinicopathologic analysis: a multicenter retrospective study in Japan[J]. Ann Gastroenterol Surg, 2024, 8(2): 273-283.
|
| [6] |
Bakkers C, van der Meer R, Roumen RM, et al. Incidence, risk factors, treatment, and survival of ovarian metastases of colorectal origin: a Dutch population-based study[J]. Int J Colorectal Dis, 2020, 35(6): 1035-1044.
|
| [7] |
Yamanishi Y, Koshiyama M, Ohnaka M, et al. Pathways of metastases from primary organs to the ovaries[J]. Obstet Gynecol Int, 2011, 2011: 612817.
|
| [8] |
Riihimäki M, Hemminki A, Sundquist J, et al. Patterns of metastasis in colon and rectal cancer[J]. Sci Rep, 2016, 6: 29765.
|
| [9] |
van der Meer R, Bakkers C, Wegdam JA, et al. Ovarian metastases in young women with colorectal cancer: a retrospective multicenter cohort study[J]. Int J Colorectal Dis, 2022, 37(8): 1865-1873.
|
| [10] |
Ursem C, Zhou M, Paciorek A, et al. Clinicopathologic characteristics and impact of oophorectomy for ovarian metastases from colorectal cancer[J]. Oncologist, 2020, 25(7): 564-571.
|
| [11] |
Thornblade LW, Han E, Fong Y. Colorectal cancer ovarian metastases[J]. Int J Gynecol Cancer, 2021, 31(8): 1137-1144.
|
| [12] |
Byun JH, Ahn JB, Kim SY, et al. The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study[J]. Korean J Intern Med, 2019, 34(1): 165-177.
|
| [13] |
Ojo J, De Silva S, Han E, et al. Krukenberg tumors from colorectal cancer: presentation, treatment and outcomes[J]. Am Surg, 2011,77(10): 1381-1385.
|
| [14] |
van der Meer R, Bakkers C, van Erning FN, et al. A propensity score-matched analysis of oncological outcome after systemic therapy for stage IV colorectal cancer: impact of synchronous ovarian metastases[J]. Int J Cancer, 2023,152(6): 1174-1182.
|
| [15] |
Xu KY, Gao H, Lian ZJ, et al. Clinical analysis of Krukenberg tumours in patients with colorectal cancer-a review of 57 cases[J]. World J Surg Oncol, 2017, 15(1): 25.
|
| [16] |
Van der Meer R, de Hingh IHJT, Bloemen JG, et al. Role of ovarian metastases in colorectal cancer (ROMIC): a Dutch study protocol to evaluate the effect of prophylactic salpingo-oophorectomy in postmenopausal women[J]. BMC Womens Health, 2022, 22(1): 441.
|
| [17] |
Ganesh K, Shah RH, Vakiani E, et al. Clinical and genetic determinants of ovarian metastases from colorectal cancer[J]. Cancer, 2017, 123(7): 1134-1143.
|
| [18] |
Jiang R, Tang J, Cheng X, et al. Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors[J]. Eur J Surg Oncol, 2009, 35(1): 92-97.
|
| [19] |
Sekine K, Hamaguchi T, Shoji H, et al. Retrospective analyses of systemic chemotherapy and cytoreductive surgery for patients with ovarian metastases from colorectal cancer: a single-center experience[J]. Oncology, 2018, 95(4): 220-228.
|
| [20] |
Tan KL, Tan WS, Lim JF, et al. Krukenberg tumors of colorectal origin: a dismal outcome--experience of a tertiary center[J]. Int J Colorectal Dis, 2010, 25(2): 233-238.
|
| [21] |
Li X, Zhang W, Ding P, et al. Clinical characteristics and prognostic factors of colorectal cancer patients with ovarian metastasis: a multicenter retrospective study[J]. Int J Colorectal Dis, 2021, 36(6): 1201-1208.
|
| [22] |
Chen C, Wang D, Ge X, et al. Prognostic factors for ovarian metastases in colorectal cancer patients[J]. World J Surg Oncol, 2021, 19(1): 220.
|
| [23] |
Willmott F, Allouni KA, Rockall A. Radiological manifestations of metastasis to the ovary[J]. J Clin Pathol, 2012, 65(7): 585-590.
|
| [24] |
Kir G, Gurbuz A, Karateke A, et al. Clinicopathologic and immunohistochemical profile of ovarian metastases from colorectal carcinoma[J]. World J Gastrointest Surg, 2010, 2(4): 109-116.
|
| [25] |
Choi HJ, Lee JH, Kang S, et al. Contrast-enhanced CT for differentiation of ovarian metastasis from gastrointestinal tract cancer: stomach cancer versus colon cancer[J]. AJR Am J Roentgenol, 2006, 187(3): 741-745.
|
| [26] |
Tanaka YO, Okada S, Satoh T, et al. Diversity in size and signal intensity in multilocular cystic ovarian masses: new parameters for distinguishing metastatic from primary mucinous ovarian neoplasms[J]. J Magn Reson Imaging, 2013, 38(4): 794-801.
|
| [27] |
Xu Y, Yang J, Zhang Z, et al. MRI for discriminating metastatic ovarian tumors from primary epithelial ovarian cancers[J]. J Ovarian Res, 2015, 8: 61.
|
| [28] |
Cai SQ, Wu MR, Ma XL, et al. Mucin-producing tumors of the ovary--preoperative differentiation between metastatic ovarian mucinous carcinoma and primary mucinous malignant tumors[J]. J Ovarian Res, 2024, 17(1): 59.
|
| [29] |
Laurent PE, Thomassin-Piana J, Jalaguier-Coudray A. Mucin-producing tumors of the ovary: MR imaging appearance[J]. Diagn Interv Imaging, 2015, 96(11): 1125-1132.
|
| [30] |
Lewis MR, Deavers MT, Silva EG, et al. Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge[J]. Am J Surg Pathol, 2006, 30(2): 177-184.
|
| [31] |
Low RN, Sebrechts CP, Barone RM, et al. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings--a feasibility study[J]. AJR Am J Roentgenol, 2009, 193(2): 461-470.
|
| [32] |
Namimoto T, Awai K, Nakaura T, et al. Role of diffusion-weighted imaging in the diagnosis of gynecological diseases[J]. Eur Radiol, 2009, 19(3): 745-760.
|
| [33] |
Sala E, Rockall A, Rangarajan D, et al. The role of dynamic contrast-enhanced and diffusion weighted magnetic resonance imaging in the female pelvis[J]. Eur J Radiol, 2010, 76(3): 367-385.
|
| [34] |
Kyriazi S, Collins DJ, Messiou C, et al. Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging--value of histogram analysis of apparent diffusion coefficients[J]. Radiology, 2011, 261(1): 182-192.
|
| [35] |
Sala E, Kataoka MY, Priest AN, et al. Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects[J]. Radiology, 2012, 263(1): 149-159.
|
| [36] |
Stukan M, Alcazar JL, Gębicki J, et al. Ultrasound and clinical preoperative characteristics for discrimination between ovarian metastatic colorectal cancer and primary ovarian cancer: a case-control study[J]. Diagnostics (Basel), 2019, 9(4): 210.
|
| [37] |
Khiewvan B, Torigian DA, Emamzadehfard S, et al. An update on the role of PET/CT and PET/MRI in ovarian cancer[J]. Eur J Nucl Med Mol Imaging, 2017, 44(6): 1079-1091.
|
| [38] |
宋望，郑洪涂，徐烨. 结肠直肠癌卵巢转移的研究进展 [J]. 外科理论与实践, 2017, 22 (3): 261-264.
|
| [39] |
Yan D, Du Y, Dai G, et al. Management of synchronous Krukenberg tumors from gastric cancer: a single-center experience[J]. J Cancer, 2018, 9(22): 4197-4203.
|
| [40] |
Kim DD, Park IJ, Kim HC, et al. Ovarian metastases from colorectal cancer: a clinicopathological analysis of 103 patients[J]. Colorectal Dis, 2009, 11(1): 32-38.
|
| [41] |
Fujiwara A, Noura S, Ohue M, et al. Significance of the resection of ovarian metastasis from colorectal cancers[J]. J Surg Oncol, 2010, 102(6): 582-587.
|
| [42] |
Mori Y, Nyuya A, Yasui K, et al. Clinical outcomes of women with ovarian metastases of colorectal cancer treated with oophorectomy with respect to their somatic mutation profiles[J]. Oncotarget, 2018, 9(23): 16477-16488.
|
| [43] |
Chung TS, Chang HJ, Jung KH, et al. Role of surgery in the treatment of ovarian metastases from colorectal cancer[J]. J Surg Oncol, 2009, 100(7): 570-574.
|
| [44] |
Liu F, Gao Z, Shen D, et al. Significance of SATB2 expression in colon cancer and its differential diagnosis in digestive tract adenocarcinoma and ovarian primary and metastatic carcinoma[J]. Pathol Res Pract, 2019, 215(7): 152430.
|
| [45] |
Moh M, Krings G, Ates D, et al. SATB2 expression distinguishes ovarian metastases of colorectal and appendiceal origin from primary ovarian tumors of mucinous or endometrioid type[J]. Am J Surg Pathol, 2016, 40(3): 419-432.
|
| [46] |
Aldaoud N, Erashdi M, AlKhatib S, et al. The utility of PAX8 and SATB2 immunohistochemical stains in distinguishing ovarian mucinous neoplasms from colonic and appendiceal mucinous neoplasm[J]. BMC Res Notes, 2019, 12(1): 770.
|
| [47] |
Dundr P, Singh N, Nožičková B, et al. Primary mucinous ovarian tumors vs. ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics[J]. Diagn Pathol, 2021, 16(1): 20.
|
| [48] |
Rius M, Fusté P, Ros C, et al. HE4 might be a more useful tumor biomarker to detect malignancy in patients with ovarian endometrioma when malignancy is suspected[J]. J Int Med Res, 2021, 49(9): 3000605211047701.
|
| [49] |
Shi J, Huang A, Song C, et al. Effect of metastasectomy on the outcome of patients with ovarian metastasis of colorectal cancer: a systematic review and meta-analysis[J]. Eur J Surg Oncol, 2023, 49(9): 106961.
|
| [50] |
Mehta AM, Bignell MB, Alves S, et al. Risk of ovarian involvement in advanced colorectal or appendiceal tumors involving the peritoneum[J]. Dis Colon Rectum, 2017, 60(7): 691-696.
|
| [51] |
Eveno C, Goéré D, Dartigues P, et al. Ovarian metastasis is associated with retroperitoneal lymph node relapses in women treated for colorectal peritoneal carcinomatosis[J]. Ann Surg Oncol, 2013, 20(2): 491-496.
|
| [52] |
何雪铼，曹钦兴，庞明辉. 直肠癌卵巢转移诊治进展[J]. 中华胃肠外科杂志, 2023, 26(3): 295-301.
|
| [53] |
Omranipour R, Abasahl A. Ovarian metastases in colorectal cancer[J]. Int J Gynecol Cancer, 2009, 19(9): 1524-1528.
|
| [54] |
李晓芬，邱萌. 结直肠癌卵巢转移的临床特征及诊治策略[J]. 肿瘤预防与治疗, 2021, 34: 166-172.
|
| [55] |
Liang JT, Lai HS, Wu CT, et al. Laparoscopic prophylactic oophorectomy plus N3 lymphadenectomy for advanced rectosigmoid cancer[J]. Ann Surg Oncol, 2007, 14(7): 1991-1999.
|
| [56] |
Nomura M, Tei M, Nishida K, et al. Aggressive surgical intervention may improve prognosis in patients with ovarian metastasis from colorectal cancer[J]. Langenbecks Arch Surg, 2023, 408(1): 313.
|
| [57] |
中国医师协会结直肠肿瘤专业委员会腹膜肿瘤专业委员会. 结直肠癌腹膜转移预防和治疗腹腔用药中国专家共识(Ⅴ2019)[J/CD]. 中华结直肠疾病电子杂志, 2019, 8(4): 329-335.
|
| [58] |
Garrett CR, George B, Viswanathan C, et al. Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary[J]. Clin Colorectal Cancer, 2012, 11(3): 191-194.
|
| [59] |
Shariff U, Seretis C, Youssef H. Management of colorectal cancer patients at high risk of peritoneal metastases[J]. J BUON, 2015, 20 (Suppl 1): S71-S79.
|
| [60] |
Leung V, Huang N, Liauw W, et al. High risk features of primary colorectal carcinomas which subsequently undergo peritonectomy[J]. Eur J Surg Oncol, 2016, 42(6): 836-840.
|
| [61] |
Kyang LS, Valle SJ, Alzahrani NA, et al. Prevention of peritoneal recurrence in high-risk colorectal cancer and evidence of T4 status as a potential risk factor[J]. ANZ J Surg, 2018, 88(10): 975-981.
|
| [62] |
中国医师协会结直肠肿瘤专业委员会. 结直肠癌腹膜转移诊治专家共识(2025版)[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(3): 193-201.
|
| [63] |
Goéré D, Daveau C, Elias D, et al. The differential response to chemotherapy of ovarian metastases from colorectal carcinoma[J]. Eur J Surg Oncol, 2008, 34(12): 1335-1339.
|
| [64] |
Kammar PS, Engineer R, Patil PS, et al. Ovarian metastases of colorectal origin: treatment patterns and factors affecting outcomes[J]. Indian J Surg Oncol, 2017, 8(4): 519-526.
|
| [65] |
Al-Busaidi IS, Bailey T, Dobbs B, et al. Complete resection of colorectal cancer with ovarian metastases combined with chemotherapy is associated with improved survival[J]. ANZ J Surg, 2019, 89(9): 1091-1096.
|
| [66] |
Kopetz S, Yoshino T, Van Cutsem E, et al. Encorafenib, Cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial[J]. Nat Med, 2025, 31(3): 901-908.
|
| [67] |
Benson AB, Venook AP, Adam M, et al. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2024, 22(2 D): e240029.
|
| [68] |
André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer[J]. N Engl J Med, 2020, 383(23): 2207-2218.
|
| [69] |
André T, Lonardi S, Wong KYM, et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142[J]. Ann Oncol, 2022, 33(10): 1052-1060.
|
| [70] |
Prager GW, Taieb J, Fakih M, et al. Trifluridine-Tipiracil and Bevacizumab in refractory metastatic colorectal cancer[J]. N Engl J Med, 2023, 388(18): 1657-1667.
|
| [71] |
Yoshino T, Di Bartolomeo M, Raghav K, et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer[J]. Nat Commun, 2023, 14(1): 3332.
|
| [72] |
Tong G, Luo Q, Pang X, et al. Retrospective analyses of complete resection combined with systemic chemotherapy and targeted therapy for patients with ovarian metastases from colorectal cancer[J]. Cancer Biother Radiopharm, 2022, 37(7): 553-559.
|
| [73] |
Xu Y, Feng Q, Chen Y, et al. Significance of surgery in the treatment of colorectal cancer ovarian metastases: a retrospective case matching study[J]. Cancer Manag Res, 2021, 13: 1087-1097.
|